FDA Analysis and Nationwide Recall

Ana Salazar Modela Tu Cuerpo Inc. initiated a nationwide voluntary consumer-stage recall of its weight loss supplement Lipofit Extreme Fat Burner 2.0 on August 27, 2026, and the FDA announced the recall on August 31. The affected product is Lot 25M12F, with an expiration date of September 2027, and was sold directly to U.S. consumers online. FDA laboratory analysis found fluoxetine in the AM tablets and 2,4-dinitrophenol (DNP) in the PM tablets, both without proper labeling. The company has ceased sales and promotion and isolated its inventory. As of the announcement, no adverse event reports had been received.

Mixing of Approved Medications and Banned Toxic Substances

Fluoxetine is an FDA-approved selective serotonin reuptake inhibitor (SSRI) marketed under the brand name Prozac, used to treat depression, bulimia nervosa, and obsessive-compulsive disorder by inhibiting the serotonin transporter (SERT). However, it is not an approved ingredient for weight loss supplements. Concurrent use with other serotonergic drugs or anticoagulants can increase the risk of serotonin syndrome, bleeding, and suicidal ideation. DNP is a mitochondrial protonophore that uncouples oxidative phosphorylation to dissipate energy as heat, but it is a toxic chemical not approved by the FDA for any use. It can cause hyperthermia, rapid heart rate, arrhythmia, seizures, cardiac arrest, and death. The simultaneous presence of these two ingredients poses an immediate patient safety risk, going beyond a mere labeling violation.

An Unapproved New Drug, Not a Clinical-Stage Product

Lipofit Extreme Fat Burner 2.0 is not a product that has undergone Phase 1, 2, or 3 clinical trials to establish efficacy and safety. It is classified by the FDA as an unapproved new drug, lacking established safety and effectiveness. Therefore, it cannot be compared to legally marketed and approved obesity treatments. This case should be viewed as an enforcement example of distributing prescription ingredients and toxic substances under the guise of a supplement. In the U.S., standard FDA-approved medications for long-term weight management include Wegovy’s semaglutide and Saxenda’s liraglutide, both GLP-1 receptor agonists, and Zepbound’s tirzepatide, a dual GIP-GLP-1 receptor agonist. Other marketed competitors include Xenical and Alli’s orlistat, Qsymia’s phentermine-topiramate, and Contrave’s naltrexone-bupropion, all of which are used under medical supervision and approved labeling.

Market and Business Risks

The U.S. weight loss supplement market is projected to grow from $8.567 billion in 2024 to $17.974 billion by 2030, with the pill segment showing the fastest growth. While the market’s growth potential and online direct-to-consumer accessibility are significant, ingredient authenticity, raw material traceability, Good Manufacturing Practice (GMP) compliance, and adverse event monitoring are critical to brand value and distribution sustainability. Although this recall involves a single lot from a non-listed company, the consumer-stage recall and sales halt entail not only revenue loss but also costs for refunds, disposal, and regulatory response. The detection of unlisted drug ingredients in online weight loss products is likely to increase the intensity of testing and enforcement across the entire sector, especially as the boundary between legal prescription obesity treatments and supplement markets becomes increasingly blurred.